Managers / Q4 2019 · view latest →
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
CIK 0001047859 · 500 CRESCENT COURT, SUITE 260, DALLAS, TX, 75201 · 2148713700
Summary
Paragon Associates & Paragon Associates II Joint Venture reported $178M in U.S.-listed holdings across 19 positions for Q4 2019.
The portfolio is heavily concentrated: Reata Pharmaceuticals alone accounts for 25.5% of reported value.
Compared with Q3 2019, the fund opened 2 new positions and exited 4.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 97.6% · $174M
- Other · 1.3% · $2M
- US DOMESTIC · 1.1% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ELVANTHEM INC | NEW | +20.0K | 20.0K | +$6M | $6M |
| FOAMIX PHARMACEUTICALS LTD | NEW | +10.0K | 10.0K | +$33,000 | $33,000 |
| WPX ENERGY INC | SOLD OUT | −200.0K | 0 | −$2M | $0 |
| AGIALAMOS GOLD INC NEW | SOLD OUT | −200.0K | 0 | −$1M | $0 |
| PTBPOTBELLY CORP | SOLD OUT | −153.2K | 0 | −$668,000 | $0 |
| NUVECTRA CORP | SOLD OUT | −200.0K | 0 | −$272,000 | $0 |
| OXYOCCIDENTAL PETE CORP | ADDED | +150.0K | 400.0K | +$5M | $16M |
| AEMAGNICO EAGLE MINES LTD | ADDED | +10.0K | 85.0K | +$1M | $5M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | REATA PHARMACEUTICALS INC | CL A | 25.50% | $45M | 222.0K |
| 2 | HUMHUMANA INChistory → | COM | 10.30% | $18M | 50.0K |
| 3 | OXYOCCIDENTAL PETE CORPhistory → | COM | 9.26% | $16M | 400.0K |
| 4 | NEMNEWMONT GOLDCORP CORPORATIONhistory → | COM | 8.55% | $15M | 350.0K |
| 5 | NVGSNAVIGATOR HOLDINGS LTDhistory → | SHS | 7.75% | $14M | 1.02M |
| 6 | ABBVABBVIE INChistory → | COM | 7.46% | $13M | 150.0K |
| 7 | CICIGNA CORP NEWhistory → | COM | 5.75% | $10M | 50.0K |
| 8 | ABXBARRICK GOLD CORPORATIONhistory → | COM | 5.22% | $9M | 500.0K |
| 9 | ELVANTHEM INChistory → | COM | 3.39% | $6M | 20.0K |
| 10 | AEMAGNICO EAGLE MINES LTDhistory → | COM | 2.94% | $5M | 85.0K |
| 11 | WPMWHEATON PRECIOUS METALS CORPhistory → | COM | 2.93% | $5M | 175.0K |
| 12 | PARRPAR PACIFIC HOLDINGS INChistory → | COM NEW | 2.61% | $5M | 200.0K |
| 13 | DHXDHI GROUP INChistory → | COM | 2.11% | $4M | 1.25M |
| 14 | EPSNEPSILON ENERGY LTDhistory → | COM | 2.01% | $4M | 1.08M |
| 15 | IRIXIRIDEX CORPhistory → | COM | 1.65% | $3M | 1.32M |
| 16 | COMMUNITY BANKERS TR CORP | COM | 1.25% | $2M | 250.0K |
| 17 | FORESTAR GROUP INC | NOTE 3.750% 3/0 | 1.13% | $2M | 2.00M |
| 18 | TUESDAY MORNING CORP | COM NEW | 0.17% | $303,000 | 163.7K |
| 19 | FOAMIX PHARMACEUTICALS LTD | SHS | 0.02% | $33,000 | 10.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $74M | 14 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $48M | 12 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $56M | 12 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $63M | 15 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $43M | 13 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $43M | 12 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $56M | 16 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $41M | 11 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $56M | 16 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $44M | 15 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $31M | 10 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $49M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 11 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $54M | 17 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $50M | 12 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $51M | 11 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $54M | 7 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $63M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $88M | 17 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $75M | 16 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $66M | 11 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $65M | 10 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $91M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 13 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $178M | 19 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $130M | 21 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $130M | 25 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $106M | 30 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.